Viridium Pacific (TSXV:VIR) CEO Jay Garnett recently conducted an interview with Green Chip Stocks Editor Jeff Siegel regarding the company’s progress in clinical research studies related to cannabis.

According to Garnett, Viridium (which is soon to be called Experion) has sponsored one of the first Phase II and Phase III clinical research studies related to post-operative pain reduction. The study is one of the most advanced cannabis-related research projects in all of Canada. Viridium began generating revenue in September 2018 through its wholesale flower business, which has developed a reputation for high-quality products and sales service.


“We started with wholesale flower and quickly established a reputation for high-quality product and sales service. Our regular customers include Emerald Therapeutics, Tilray, High Point, to name a few. We have now entered into the Adult Use market with several Canadian provincial distributors. Whilst Experion was not the first to market, we were one of the fastest products to sell out with increased re-orders across the board,” said Jay Garnett, CEO of Viridium Pacific.

Garnett also went on to explain Viridium’s business strategy, which is aimed at generating multiple revenue streams and business opportunities. The company has established a strong reputation in B2B sales, offering clones to other licensed producers looking to establish their cultivation operations.

To read more of the conversation between Garnett and Siegel, click here.

 

 

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less